Genmab — September 2019
-
By Garvins lille survey viste: The Crowd has predicted that ofatumumab will reduce the ARR (relative annualised relapse rate) and CDP (confirmed disability progression) compared to teriflunomide by 41.2% (interquartile range=34.0-49.0%) and 29.3% (interquartile range=20.0-37.3%), respectively.
-
Link til ovenstående https://multiple-sclerosis-research.org/2019/09/results-time/
-
Han er gået under jorden
https://twitter.com/GavinGiovannoni -
-
Nu mangler vi så bare, at Novartis fortsætter det som GSK startede, nemlig at forsøge med ofa i RA, der jo også er en autoimmun lidelse. Og når der nu var så god respons i rms, hvorfor så ikke. GSK nåede faktisk at køre et fase 1 forsøg med sc ofa i RA.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind